Evidence map›Paper›PMID 25889633›Full record

Trial reportMalaria journal2015

Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali.

Hamma Maiga, Abdoulaye A Djimde, Abdoul H Beavogui, Ousmane Toure, Mamadou Tekete, Cheick Papa O Sangare, Antoine Dara, Zoumana I Traore, Oumar B Traore, Souleymane Dama and 6 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Malaria journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Biomedicines · 2016
    Article
  7. Investigating the Comparative Effects of Six Artemisinin-based Combination Therapies onNigerian medical journal : journal of the Nigeria Medical Association
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Hamma MaigaMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. hmaiga@icermali.org.
Abdoulaye A DjimdeMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. adjimde@icermali.org.
Abdoul H BeavoguiMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. beavoguia_h@yahoo.com.
Ousmane ToureMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. obtoure@icermali.org.
Mamadou TeketeMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. mtekete@icermali.org.
Cheick Papa O SangareMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. oumar@icermali.org.
Antoine DaraMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. tonydara@icermali.org.
Zoumana I TraoreMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. zouisaac@gmail.com.
Oumar B TraoreMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. bila@icermali.org.
Souleymane DamaMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. dama@icermali.org.
Christelle N'DongMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. chris_ndong@hotmail.com.
Hamidou NiangalyMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. hniangaly@icermali.org.
Nouhoum DialloMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. nouhoumd@icermali.org.
Demba DembeleMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. ddembele@icermali.org.
Issaka SagaraMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. isagara@icermali.org.
Ogobara K DoumboMolecular Epidemiology and Drug Resistance Unit, University of Sciences Techniques and Technology of Bamako, PO Box: 1805, Bamako, Mali. okd@icermali.org.
University of Bamako · ML

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlasmodium falciparum resistance to artemisinin has been reported in South-East Asia. Long half-life drugs are increasingly being used for malaria prevention. The potential spread of parasite resistance to these regimens is real and makes regular efficacy surveillance a priority.

methodsFrom August to December 2004 and July to December 2005, a randomized open label trial of sulphadoxine-pyrimethamine (SP) + artesunate (AS) versus SP + amodiaquine (AQ), and SP alone, was conducted in two villages of Mali. PCR was used to distinguish new infections from recrudescent P. falciparum infections. Patients were followed for 28 days to assess treatment efficacy.

resultsOverall 912 children aged between six to 59 months, with uncomplicated P. falciparum malaria were recruited. Baseline characteristics were similar in the three treatment arms. Crude ACPRs were 94.9%; 98.6% and 93.5% for SP + AS; SP + AQ and SP alone arms respectively (SP + AS versus SP + AQ, p = 0.01; SP + AS versus SP, p = 0.5; SP + AQ versus SP, p = 0.001). After PCR adjustment, cACPRs were 99%; 100% and 97.2% for SP + AS; SP + AQ and SP alone arms, respectively (SP + AS versus SP + AQ, p = 0.25; SP + AS versus SP, p = 0.12; SP + AQ versus SP, p = 0.007).

conclusionSulphadoxine-pyrimethamine + amodiaquine therapy was as efficacious as sulphadoxine-pyrimethamine + artesunate, but more efficacious than sulphadoxine-pyrimethamine alone in the treatment of uncomplicated P. falciparum malaria in Mali.

Indexed as

AmodiaquineAntimalarialsArtemisininsChild, PreschoolDrug CombinationsFemaleHumansInfantMalaria, FalciparumMaleMaliPyrimethamineSulfadoxineAmodiaquineAntimalarialsArtemisininsDrug Combinationsfanasil, pyrimethamine drug combinationPyrimethamineSulfadoxinesulfadoxine-pyrimethamine-artesunate

Identifiers

PMID25889633
PMCPMC4326408
OpenAlexW2116757286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.